What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study

被引:9
|
作者
Shim, Geumsook [1 ]
Park, Hye Youn [1 ]
Jang, Joon Hwan [1 ]
Kim, Euitae [1 ]
Park, Hye Yoon [1 ]
Hwang, Jae Yeon [1 ,2 ]
Kim, Sung Nyun [1 ]
Jang, Go-Eun [3 ]
Kwon, Jun Soo [1 ,2 ,3 ]
机构
[1] Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea
[2] Seoul Natl Univ, Brain & Cognit Sci WCU Program, Coll Nat Sci, Seoul 110744, South Korea
[3] SNU MRC, Clin Cognit Neurosci Ctr, Neurosci Inst, Seoul, South Korea
关键词
escitalopram; high dose; obsessive-compulsive disorder; selective serotonin reuptake inhibitors; SEROTONIN REUPTAKE INHIBITORS; POSITRON-EMISSION-TOMOGRAPHY; SOCIAL ANXIETY DISORDER; DOUBLE-BLIND; PREFRONTAL CORTEX; 20; MG; PLACEBO; PHARMACOTHERAPY; DOPAMINE; TRANSPORTER;
D O I
10.1097/YIC.0b013e32834a5c09
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study explored the efficacy and tolerability of very high doses (maximum dose of >40 mg/day), high doses (maximum dose of 25-40 mg/day), and standard doses (maximum dose of <= 20 mg/day) of escitalopram (ESC) as an anti-obsessive-compulsive disorder treatment in a naturalistic clinical setting. We reviewed the medical records of all patients with obsessive-compulsive disorder (n = 246) who had taken ESC between May 2006 and September 2009, and assigned Clinical Global Impression (CGI) scores, retrospectively. Of the total sample, 24.4, 38.2, and 37.4% patients received very high, high, and standard doses of ESC, and the mean daily maximum doses of ESC were 57.3 +/- 12. mg, 33.9 +/- 5.4 mg, and 13.4 +/- 5.8 mg, respectively. The CGI-Severity scores in each group decreased significantly after treatment with ESC, as evidenced by response rates (i.e. CGI-Improvement scores of 1 or 2) of 46.3, 43.2, and 26.2%, respectively. Although some adverse events increased in a dose-dependent manner, most could be managed with an ESC dose adjustment. These results imply that doses less than or equal to 40 mg/day ESC are sufficient for symptomatic improvement with good tolerability for most patients. Very high doses of ESC, on the other hand, can be considered for patients with inadequate therapeutic responses to the administration of 40 mg/day ESC. Int Clin Psychopharmacol 26:284-290 (C) 2011 Wolters Kluwer Health | Lippincott Williams & Wilkins.
引用
收藏
页码:284 / 290
页数:7
相关论文
共 50 条
  • [41] An open-label trial of escitalopram in the treatment of impulsive-compulsive internet usage disorder
    Dell'Osso, B
    Altamura, AC
    Hadley, SJ
    Baker, BR
    Hollander, E
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S82 - S83
  • [42] Deep brain stimulation for severe treatment-resistant obsessive-compulsive disorder: An open-label case series
    Farrand, Sarah
    Evans, Andrew H.
    Mangelsdorf, Simone
    Loi, Samantha M.
    Mocellin, Ramon
    Borham, Adam
    Bevilacqua, JoAnne
    Blair-West, Scott
    Walterfang, Mark A.
    Bittar, Richard G.
    Velakoulis, Dennis
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 (07): : 699 - 708
  • [43] A naturalistic study of referred children and adolescents with obsessive-compulsive disorder
    Masi, G
    Millepiedi, S
    Mucci, M
    Bertini, N
    Milantoni, L
    Arcangeli, F
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2005, 44 (07): : 673 - 681
  • [44] Metabolic syndrome and obsessive-compulsive disorder: a naturalistic Italian study
    Albert, Umberto
    Aguglia, Andrea
    Chiarle, Alice
    Bogetto, Filippo
    Maina, Giuseppe
    GENERAL HOSPITAL PSYCHIATRY, 2013, 35 (02) : 154 - 159
  • [45] Repetitive transcranial magnetic stimulation on supplementary motor area in the treatment of refractory obsessive-compulsive disorder: open-label pilot study
    Koo, B. H.
    Seo, W. S.
    Cheon, E. J.
    Kim, H. K.
    Lee, Y. J.
    Lee, S. W.
    Yun, S. H.
    Lee, G. W.
    Choi, J. H.
    Keum, M. S.
    Choi, W. S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2016, 26 : S619 - S620
  • [46] Pharmacotherapy in Paediatric Obsessive-Compulsive Disorder A Naturalistic, Retrospective Study
    Masi, Gabrielle
    Millepiedi, Stefania
    Perugi, Giulio
    Pfanner, Chiara
    Berloffa, Stefano
    Pari, Cinzia
    Mucci, Maria
    CNS DRUGS, 2009, 23 (03) : 241 - 252
  • [47] Escitalopram Efficacy in Obsessive-Compulsive Disorder Comorbid with Bipolar Disorder
    Herstowska, Marta
    Cubala, Wieslaw Jerzy
    DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES, 2013, 26 (01): : 115 - 116
  • [48] Open trial of flutamide for treatment of obsessive-compulsive disorder
    Altemus, M
    Greenberg, BD
    Keuler, D
    Jacobson, KR
    Murphy, DL
    JOURNAL OF CLINICAL PSYCHIATRY, 1999, 60 (07) : 442 - 445
  • [49] Maintenance treatment for obsessive-compulsive disorder: Findings from a naturalistic setting
    Peselow, Eric D.
    Pizano, Demetria R.
    Ishak, Waguih William
    ANNALS OF CLINICAL PSYCHIATRY, 2015, 27 (01) : 25 - 32
  • [50] Differential Efficacy of Memantine for Obsessive-Compulsive Disorder vs. Generalized Anxiety Disorder: An Open-Label Trial
    Feusner, Jamie D.
    Kerwin, Lauren
    Saxena, Sanjaya
    Bystritsky, Alexander
    PSYCHOPHARMACOLOGY BULLETIN, 2009, 42 (01) : 81 - 93